| abstract |
The present invention relates to a mutant form of Bik having anti-cell proliferative activity and / or pro-apoptotic activity. In certain embodiments, the Bik polypeptide includes substitutions at Thr33 and Ser35, and in some embodiments phosphorylation at these sites is inhibited. In more specific embodiments, these types are useful for cancer therapy, particularly when administered in combination with liposomes. In embodiments where the mutant Bik polynucleotide is administered in cancer therapy, the polynucleotide can be regulated in a tissue specific manner. |